Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Viral Recombination

Viral Recombination

Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.

Viral Structure

Viral Structure

Viruses are extraordinarily diverse in shape and size, but they all have several structural features in common. All viruses have a core that contains a DNA- or RNA-based genome. The core is surrounded by a protective coat of proteins called the capsid. The capsid is composed of subunits called capsomeres. The capsid and genome-containing core are together known as the nucleocapsid.

Physiological Barriers

Physiological Barriers

Physiological barriers are semi-permeable cellular structures restricting drug diffusion into intracellular compartments and tissues. There are six types of physiological barriers: blood endothelial, cell membrane, blood-brain, blood-cerebrospinal fluid (CSF), blood-placenta, and blood-testis barriers.
The blood endothelial barrier is the most porous of these. It allows all small ionized, un-ionized, and lipophilic molecules to pass through the endothelial lining into the interstitial space...

Antibody Structure

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...

Mucosal Barrier of the Stomach

Mucosal Barrier of the Stomach

The gastric glands contain parietal cells that secrete hydrochloric acid (HCl) for digestion. The cells secrete HCl because it is highly corrosive and essential for breaking down food. To achieve this, they secrete hydrogen and chloride ions into the lumen of the gastric glands, which combine to form HCl.
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...

Surface Membrane Barriers

Surface Membrane Barriers

The skin and mucous membranes serve as the primary line of defense against pathogens by providing both physical and chemical protection. These barriers are essential in preventing the entry and establishment of microbes, thereby maintaining the integrity of the host.
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Vaccination elicits HIV broadly neutralizing antibodies in primates.

Nature·2026

Same author

Structure and functional diversity of antibodies targeting the <i>P. falciparum</i> circumsporozoite protein C-terminal domain.

bioRxiv : the preprint server for biology·2026

Same author

Vaccine elicitation of HIV broadly neutralizing antibodies from genome-edited B cells in non-human primates and derived lymphoid organoids.

Gene therapy·2026

Same author

Deep learning-enabled scaffolding of spatial arrays of PfCSP epitopes.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV V2 apex broadly neutralizing antibody development.

Science immunology·2026

Same author

Rapidly acquired HIV-1 neutralization breadth in a rhesus V2 apex knockin mouse model after a single bolus immunization.

Science immunology·2026

Search research articles

Related Experiment Video

Updated: Jan 20, 2026

Testing the Physiological Barriers to Viral Transmission in Aphids Using Microinjection

Testing the Physiological Barriers to Viral Transmission in Aphids Using Microinjection

Published on: May 14, 2008

Antibody barriers to going viral.

Dennis R Burton^1,2

¹The Scripps Research Institute, La Jolla, CA burton@scripps.edu.

The Journal of Experimental Medicine

|August 25, 2019

Summary

Antibody effector function is crucial for protection against alphavirus infection in vivo. This study highlights how antibody mechanisms in living organisms differ from in vitro neutralization, emphasizing effector functions for viral protection.

More Related Videos

A Human Blood-Brain Interface Model to Study Barrier Crossings by Pathogens or Medicines and Their Interactions with the Brain

A Human Blood-Brain Interface Model to Study Barrier Crossings by Pathogens or Medicines and Their Interactions with the Brain

Published on: April 9, 2019

Author Spotlight: Advancing the Use of Tissue Chip Technology for Studying Human Tissues

Author Spotlight: Advancing the Use of Tissue Chip Technology for Studying Human Tissues

Published on: January 12, 2024

Related Experiment Videos

Last Updated: Jan 20, 2026

Testing the Physiological Barriers to Viral Transmission in Aphids Using Microinjection

Testing the Physiological Barriers to Viral Transmission in Aphids Using Microinjection

Published on: May 14, 2008

A Human Blood-Brain Interface Model to Study Barrier Crossings by Pathogens or Medicines and Their Interactions with the Brain

A Human Blood-Brain Interface Model to Study Barrier Crossings by Pathogens or Medicines and Their Interactions with the Brain

Published on: April 9, 2019

Author Spotlight: Advancing the Use of Tissue Chip Technology for Studying Human Tissues

Author Spotlight: Advancing the Use of Tissue Chip Technology for Studying Human Tissues

Published on: January 12, 2024

Area of Science:

Immunology
Virology
Infectious Diseases

Background:

Antibody neutralization of viruses in vitro is a common measure of protection.
The in vivo mechanisms by which antibodies protect against viral infections are often not fully understood.
Alphaviruses represent an emerging threat, necessitating a clear understanding of protective immunity.

Purpose of the Study:

To investigate the role of antibody effector functions in protection against alphavirus infection in vivo.
To elucidate the mechanisms underlying antibody-mediated protection against viral exposure.
To determine the importance of antibody effector function beyond simple neutralization.

Main Methods:

Investigated a large panel of antibodies with varying neutralization and effector capabilities.
Utilized a mouse model to assess protection against an emerging alphavirus.
Analyzed the correlation between antibody effector functions and in vivo protection.

Main Results:

Demonstrated that antibody effector function significantly contributes to protection against alphavirus infection in vivo.
Showed that in vitro neutralization capacity does not fully predict in vivo efficacy.
Identified specific antibody effector mechanisms critical for controlling viral spread.

Conclusions:

Antibody effector functions play a vital role in mediating protection against alphavirus infection in a living organism.
Relying solely on in vitro neutralization assays may underestimate the protective potential of certain antibodies.
Understanding antibody effector mechanisms is essential for developing effective antibody-based therapies against viral diseases.